January 27, 2023 10:35 AM ESTUpdated 02:25 PM
People
R&D

Dutch biotech starts liq­ui­da­tion af­ter end­ing PhI­II in GVHD

Kyle LaHucik

Senior Reporter

A 13-year-old Dutch biotech is go­ing through a liq­ui­da­tion process af­ter an un­ex­pect­ed end to its Phase III tri­al test­ing whether its com­bi­na­tion of two …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times